Group 1 - The pharmaceutical industry is experiencing continuous catalytic developments, with significant capital inflow into the Science and Technology Innovation Drug ETF (Guotai, 589720), which has seen nearly 1 billion yuan in net inflows over the past 20 days, indicating active capital positioning [1] - According to Zhongtai Securities, the raw material drug/intermediate industry has undergone 4-5 years of price decline, and with the rise in commodity and upstream chemical prices, a price improvement is expected. Most API product prices are at historical low levels, with limited profit margins and a low probability of further decline, showing a significant stabilization trend [1] - Innovative drug sectors such as small nucleic acids, peptides, and ADC toxins are continuously catalyzing the industry chain, contributing new business increments for raw material drug companies [1] Group 2 - The Science and Technology Innovation Drug ETF (Guotai, 589720) tracks the Science and Technology Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%. This index focuses on new drug research and development driven by technological innovation, covering companies in the biopharmaceutical and chemical pharmaceutical sectors with high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry, with a focus on growth style in its allocation [1]

Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Core Viewpoint - The company has successfully completed the construction of a high-purity solvent project with an annual production capacity of 20,000 tons, which has effectively improved its capacity utilization rate [1] Group 1: Production and Capacity - The Changyi Tianyu project has officially commenced operations, leading to an increase in capacity utilization [1] - The company continues to solidify its position as a leading manufacturer of sartans, with a significant focus on the integration of raw materials and formulations [1] Group 2: Market Position and Revenue - The company's revenue from both raw materials and formulation products is showing a growth trend [1] - Several products have obtained CEP certification or are actively pursuing FDA certification, with revenue contributions expected to materialize as global market expansion progresses [1]

2月 4日，《浙江省"十五五"高质量发展建设共同富裕示范区规划》公开征求意见。其中提到，打造人工智能创新发展高地。统筹规划全省算力 资源，构建多层次算力服务体系。实施"芯模联动"行动，打造世界一流"基础+垂类"模型群，着力营造最优开源开放生态。加快国家数据要素综 合试验区建设。 深化拓展"人工智能+" ，争创人工智能国家应用基地。推动构建人工智能全产业链协同发展格局。 2月4日，A股三大指数走势分化，其中沪指上涨0.17%。截至10:57，科创100ETF华夏（588800.SH）下跌1.71%。其他宽基指数中，上证50涨 0.30%，科创50跌2.14%，创业板50跌1.90%，北证50跌0.84%。 | 画线 | | | | 浄值 | | | 叠 复权 窗 区 信息 加自选 | | | | | 科创100ETF华夏 588800 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 5 MA30: 1.479 MA60: 1.373 | | | | | | | | | ...

截至1月30日，常山药业股东户数4.17万，较上期增加0.59%；人均流通股22018股，较上期减少0.59%。 2025年1月-9月，常山药业实现营业收入6.81亿元，同比减少13.11%；归母净利润-4481.74万元，同比减 少714.77%。 2月3日，常山药业涨3.29%，成交额8.68亿元。两融数据显示，当日常山药业获融资买入额7568.79万 元，融资偿还8157.33万元，融资净买入-588.54万元。截至2月3日，常山药业融资融券余额合计25.08亿 元。 融资方面，常山药业当日融资买入7568.79万元。当前融资余额25.08亿元，占流通市值的5.44%，融资 余额超过近一年80%分位水平，处于高位。 融券方面，常山药业2月3日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年50%分位水平，处于较高位。 资料显示，河北常山生化药业股份有限公司位于中国(河北)自由贸易试验区正定片区正定县高新技术产 业开发区南区梦龙街71号，成立日期2000年9月28日，上市日期2011年8月19日，公司主营业务涉及肝素 系列产 ...

证券日报网讯 2月3日，艾迪药业在互动平台回答投资者提问时表示，公司股价波动受宏观经济、市场 环境、行业因素及投资者情绪等多重因素影响，具有不确定性。目前公司各项经营活动均正常开展，经 营基本面稳定，不存在应披露而未披露的重大事项。公司管理层始终致力于做好经营管理工作，持续提 升公司核心竞争力，努力为投资者创造长期价值。二级市场股价走势受多方面因素综合作用，敬请广大 投资者理性看待市场波动，注意投资风险。 ...

Core Viewpoint - The board of directors of Heng Rui Medicine has announced a postponement of the board election, extending the terms of the current board members and senior management until February 1, 2026, to ensure governance stability and avoid disruptions in research and commercialization processes [1][7][16]. Group 1: Board and Management Changes - The current board of directors, including key executives such as Chairman Sun Piaoyang and President Dai Hongbin, will continue their roles until the new board is elected [3][12]. - The postponement of the board election may be influenced by factors such as strategic continuity, shareholder opinion coordination, and candidate selection [7][16]. - As of February 3, 2023, Heng Rui Medicine's A-share price was 57.47 yuan, with a market capitalization of 381.44 billion yuan, while its Hong Kong stock price was 67 HKD, with a market capitalization of 444.69 billion HKD [7][16]. Group 2: Financial Performance and Business Development - In the first three quarters of 2024 and 2025, Heng Rui Medicine reported revenues of 27.985 billion yuan and 23.188 billion yuan, representing year-on-year growth of 22.63% and 14.85%, respectively [8][17]. - The net profits for the same periods were 6.337 billion yuan and 5.751 billion yuan, with year-on-year increases of 47.28% and 24.50% [8][17]. - The company achieved significant revenue from its innovative drug business, with sales and licensing income of 9.561 billion yuan in the first half of 2025, accounting for 60.66% of total revenue [9][18]. Group 3: Market Position and Competitive Landscape - Despite strong growth, Heng Rui Medicine faces challenges from competitors, particularly in the innovative drug sector, where it must contend with similar products from other companies [10][21]. - The company’s overseas revenue was approximately 716 million yuan in 2024, constituting only 2.86% of total revenue, highlighting a significant gap compared to competitors like BeiGene, which had over 60% of its revenue from international markets [9][18]. - The oncology segment remains the largest revenue source for Heng Rui Medicine, generating approximately 14.587 billion yuan in 2024, with a gross margin of 92.57% [19][20].

Core Viewpoint - Yifan Pharmaceutical (002019) announced that the company and its controlling subsidiaries have not provided guarantees for units outside the scope of the consolidated financial statements, nor do they have overdue guarantees, litigation-related guarantee amounts, or losses due to judgments against guarantees [1] Group 1 - The company has not provided any guarantees for units outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - The company has not incurred any losses due to judgments related to guarantees [1]

（文章来源：证券日报） 证券日报网讯 2月3日，贵研铂业在互动平台回答投资者提问时表示，公司铂抗癌药是仿制药，目前已 完成国家药监局注册申报用小试阶段工艺研究以及实验室公斤级别的放大试生产，后续将开展商业化批 量的试生产以及工艺验证工作。 ...